Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer
| Autor: | Amelia D'Alessio, Antonella De Luca, Nicola Normanno, Marianeve Carotenuto, Marianna Gallo, Daniela Frezzetti, Monica R. Maiello |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug Pyridines media_common.quotation_subject Antineoplastic Agents Breast Neoplasms Palbociclib Toxicology Piperazines 03 medical and health sciences 0302 clinical medicine Breast cancer Cyclin-dependent kinase Biomarkers Tumor Humans Medicine Protein Kinase Inhibitors media_common Pharmacology biology business.industry Kinase Patient Selection Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 General Medicine Cell cycle medicine.disease 030104 developmental biology Hormone receptor 030220 oncology & carcinogenesis Cancer research biology.protein Female business Hormone |
| Zdroj: | Expert Opinion on Drug Metabolism & Toxicology. 14:891-900 |
| ISSN: | 1744-7607 1742-5255 |
| DOI: | 10.1080/17425255.2018.1514720 |
| Popis: | Cyclin-dependent kinases (CDKs) 4 and 6 regulate the transition from G0/G1-phase to S-phase of the cell cycle and have been identified as key drivers of proliferation in hormone receptor (HR)-positive breast cancer. The CDK4/6 inhibitor palbociclib in combination with endocrine therapy has been approved for treatment of HR-positive/HER2-negative breast cancer patients. Areas covered: In this article, we provide an update of the data on pharmacodynamics, pharmacokinetics, preclinical, and clinical studies of palbociclib in breast cancer. We performed a search of data on palbociclib in the PubMed and the clinicaltrials.gov databases, in the FDA website and in the ASCO and AACR proceedings. Expert opinion: In order to optimize the clinical outcome of HR-positive breast cancer patients treated with palbociclib, predictive biomarkers allowing patient selection are urgently needed. A recent study suggested that early dynamics of PIK3CA mutations in circulating tumor DNA might be a potential predictive biomarker for CDK4/6 inhibitors. Several clinical trials are ongoing with the aim to explore the activity of combinations of palbociclib with targeted agents and/or immunotherapy in the different subtypes of breast cancer in both metastatic and early phases of the disease. These combinations might allow improving the sensitivity and overcoming mechanisms of resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|